Key Trend Shaping The Ilumya Market In 2025: Advancing Treatment For Moderate-To-Severe Plaque Psoriasis

March 07, 2025 09:42 AM AEDT | By EIN Presswire
 Key Trend Shaping The Ilumya Market In 2025: Advancing Treatment For Moderate-To-Severe Plaque Psoriasis
Image source: EIN Presswire

LONDON, GREATER LONDON, UNITED KINGDOM, March 6, 2025 /EINPresswire.com/ -- Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How Has the Ilumya Market Performed Historically, and What Are Future Projections?
• The Ilumya market has demonstrated strong historical growth, achieving a high compound annual growth rate (HCAGR) in recent years.
• The market expanded from $XX million in 2024 to $XX million in 2025, reflecting a compound annual growth rate (CAGR) of XX%.
• The key factors driving this growth include:
o Rising prevalence of rheumatoid arthritis
o Increased demand for psoriasis treatments
o Higher investments in drug research and development (R&D)

Get Your Free Sample Market Report: https://www.thebusinessresearchcompany.com/sample.aspx?id=20096&type=smp

What Does the Future Hold for the Ilumya Market?
• The Ilumya market is anticipated to expand further, reaching $XX million by 2029, with a forecasted CAGR of XX%.
• This growth is driven by:
o Increasing incidence of plaque psoriasis
o Rising demand for Tildrakizumab
o Greater adoption of combination therapies
• Key emerging trends shaping the market include:
o Breakthrough innovations in treatment approaches
o Growing emphasis on biological therapies for psoriasis management
o Advancements in drug delivery systems for enhanced patient outcomes

Order Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/ilumya-global-market-report

What Factors Are Fueling the Growth of the Ilumya Market?
The Ilumya market is expected to expand due to the increasing prevalence of psoriasis, a chronic autoimmune condition that leads to excessive skin cell production, causing red, scaly patches. The surge in cases is influenced by:
• Improved diagnostic techniques
• Higher public awareness of psoriasis
• Environmental factors and genetic predisposition
• Obesity and certain medications that trigger flare-ups
• Infections that exacerbate the condition
Ilumya serves as an effective treatment for moderate-to-severe plaque psoriasis, as it reduces inflammation and slows abnormal skin cell growth, improving patient quality of life.

Which Companies Are Leading the Ilumya Market?
Leading pharmaceutical companies shaping the Ilumya market include Sun Pharmaceutical Industries Ltd., which has made significant investments in manufacturing, research, and marketing to drive market expansion.

What Are the Key Trends in the Ilumya Market?
A significant trend in the Ilumya market is the development of advanced treatments for moderate-to-severe plaque psoriasis.
For instance, Sun Pharmaceutical Industries Inc. introduced five new data abstracts on Ilumya in March 2022. These findings, presented at the 2022 American Academy of Dermatology (AAD) Annual Meeting, emphasized the safety and effectiveness of Ilumya in patients with moderate-to-severe plaque psoriasis, reinforcing its role as a leading treatment.

How Is the Ilumya Market Segmented?
The Ilumya market is categorized into the following segments:
1. By Patient Demographics: Pediatric Patients, Adult Patients
2. By Distribution Channel: Hospitals, Specialty Clinics, Online Pharmacies, Retail Pharmacies
3. By Application: Plaque Psoriasis, Psoriatic Arthritis, Other Inflammatory Conditions


Which Regions Dominate the Ilumya Market?
In 2024, North America held the largest market share due to its strong healthcare infrastructure and high adoption of biologic therapies. However, Asia-Pacific is projected to be the fastest-growing region in the forecast period, driven by rising healthcare investments and increasing psoriasis prevalence. Other regions covered include Western Europe, Eastern Europe, South America, the Middle East, and Africa.

Browse Through More Similar Reports By The Business Research Company:

Rituximab Biosimilars Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/rituximab-biosimilar-global-market-report

Arthritis Monoclonal Antibodies Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/arthritis-monoclonal-antibodie-global-market-report

Orthobiologics Devices And Equipment Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/orthobiologics-devices-and-equipment-global-market-report

Learn More About The Business Research Company
The Business Research Company provides in-depth research and insights through a vast collection of 15,000+ reports spanning 27 industries and over 60 geographies. Backed by 1,500,000 datasets, extensive secondary research, and expert insights from industry leaders, we equip you with the knowledge needed to stay ahead in the market.

Our flagship offering, the Global Market Model, is a leading market intelligence platform that delivers comprehensive and up-to-date forecasts to support strategic decision-making.

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
[email protected]
Visit us on social media:
Facebook
X
LinkedIn

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.